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Abstract
Sarcomatoid renal cell carcinoma is a highly aggressive tumor. It is not a distinct histologic entity as it can be found in any
subtypes of renal cell carcinoma. Recent molecular and genetic evidence suggest that sarcomatoid component is transformed
from a common progenitor of the associated renal cell carcinoma, and the TP53 gene plays a pivotal role in this process.
The presence of sarcomatoid carcinoma indicates poor prognosis, which also correlates with the amount of the sarcomatoid com-
ponent. Therefore, the presence and quantity of sarcomatoid component should be reﬂected in pathology reports. However,
pathology reporting seems to vary among laboratories prompting the need for a uniﬁed reporting system.We propose a pathology
reporting system similar to that of transformed follicular lymphoma that is consistent with the molecular pathogenesis to ensure
uniform reporting.
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Introduction
Renal cell sarcoma used to be the common terminology for
all malignant mesenchymal neoplasms of the kidney until
Grifﬁth, in 1949, described that many of them also contained
renal cell carcinoma (RCC) (1, 2). Carcinosarcoma was then
used to better reﬂect the nature of these tumors. Later, the
term sarcomatoid RCC was used by Farrow et al. because
they believed these tumors were metaplastic transformation
of carcinoma. They regarded it as a separate histologic type
to stress the highly aggressive behavior (3). Since sarcomatoid
transformation can be present in any RCC subtypes, in current
classiﬁcation schemes, sarcomatoid RCC is not a distinct patho-
logic subtype of RCC, rather a speciﬁc histologic feature (2, 4).
Since clear cell RCC is the most common renal carcinoma,
79%–87% of sarcomatoid RCC are associated with this subtype.
Chromophobe RCC (Figure 1A and B) accounts for 7%–7.5%,
followed by papillary (4%–8%), unclassiﬁed (2%–4%), and col-
lecting duct (2%) RCC (5, 6). About 15% of patients who
develop stage IV disease have sarcomatoid RCC (7). Sarcoma-
toid RCC is an independent prognostic factor (8–10) and is
associated with death from RCC of all three subtypes: clear
cell, papillary, and chromophobe. The presence of sarcomatoid
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RCC is also signiﬁcantly associated with poor outcome even in
Fuhrman grade IV clear cell RCC (6). However, some investi-
gators found sarcomatoid RCC did not signiﬁcantly correlate
with survival (11, 12).
About 3% of renal carcinomas are purely sarcomatoid (13).
The generally accepted explanation is that the sarcomatoid
component overgrows and replaces the carcinoma with
which it is originally associated (13). Therefore, in practice,
thorough gross and histological examination is critical.
Although carcinoma component cannot be identiﬁed, the
malignant spindle cells are generally positive for keratin and
PAX8 (Figure 1C–F) (14, 15), which distinguish from bona
ﬁde sarcoma of the kidney. Sarcomatoid RCC demonstrates
desmosomal cell junctions and poorly formed primitive cell
junctions by ultrastructural analysis (16, 17). This intriguing
phenomenon of sarcomatoid transformation is not only inter-
esting at a molecular level but also important for patient man-
agement with the expanding horizons of targeted therapies.
Herein, we brieﬂy review the recent progress in the molecular
genetics of sarcomatoid RCC and the potential clinical appli-
cation. We also propose an easy and reproducible system for
reporting the pathology of sarcomatoid RCC.
Genetic alterations in sarcomatoid RCC
Jones et al., using X-chromosome inactivation analysis, found
that both sarcomatoid and carcinomatous components of
RCCs are derived from the same progenitor cell (18)
Figure 1. (A) Chromophobe carcinoma mixed with sarcomatoid carcinoma, (B) high power of (A), (C) pure sarcomatoid carci-
noma invading the renal parenchyma, (D) high power of the sarcomatoid carcinoma, (E) positive CAM 5.2 (keratin) staining, and
(F) positive PAX8 staining.
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suggesting that the sarcomatoid cells may undergo a morpho-
logic transformation from carcinoma. This mechanism
is known as epithelial to mesenchymal transition (EMT)
(13, 18). In this process, carcinoma cells lose epithelial pheno-
type and gain mesenchymal feature (19, 20). Recent clinical
and preclinical results showed that the disrupted changes
leading to EMT can be potential targets of treatment for
RCC patients (20). Jiang et al. analyzed 12 cases of sarcoma-
toidRCCusing comparative genomic hybridization technique
and found that chromosomal gains are less frequent than chro-
mosomal losses. In the sarcomatoid component of RCC,
alteration in chromosomes 4q, 7p21-22, 11q22-23, and 13q
were identiﬁed (21). Brunelli and colleagues found frequent
gains of chromosomes 1, 2, 6, 10, and 17 in sarcomatoid chro-
mophobe RCC in contrast to the loss of these chromosomes in
classic chromophobe RCC. These multiple gains of chromo-
somes were identiﬁed in both carcinomatous and sarcomatoid
components (22). Our group recently reported that sarcoma-
toid transformation in RCC is associated with increased
chromosomal imbalances with gains of 1q and 8q, losses of
9q, 15q, 18p/q, and 22q compared to non-sarcomatoid RCC
(23). Frequently, sarcomatoid RCCs do not have the charac-
teristic chromosome abnormality of the histologic type of
RCC it is associated with, which suggests that sarcomatoid
component may arise from genetically atypical subclonal
tumor cells or from the same progenitor cells (24, 25).
Molecular alterations
The vonHippel–Lindau (VHL) gene plays a central role in the
pathogenesis of clear cell RCC. The important function of
pVHL is to target and degrade hypoxia inducible factor
(HIF). HIF can activate downstream targets including
GLUT1, CA9, and VEGF. Tickoo et al. assessed the expres-
sion of HIF in 34 cases of sarcomatoid RCCs. Sarcomatoid
RCC associated with clear cell RCC maintained higher HIF
pathway expression compared to that associated with non-
clear cell RCC (26). Interestingly, Oda et al. found that carci-
nomatous components had lower TP53 mutation (14%, 2/14)
compared to sarcomatoid component (79%, 11/14) (27).
Malouf et al. analyzed 26 cases of sarcomatoid RCC using
genomic proﬁling (including 37 introns from 19 commonly
rearranged genes and 3230 exons of 236 in carcinoma). They
performed genomic proﬁling of both sarcomatoid and carci-
nomatous components in three cases, two of which showed
identical mutational proﬁles, and another case harbored com-
monly disrupted genes. The most frequently involved genes
included TP53 (42%), CDKN2A (27%), VHL (35%), and
NF2 (19%) (28). Bi et al. studied normal, carcinomatous,
and sarcomatoid components of 21 cases of sarcomatoid
RCC using exome sequencing. They found that the carcino-
matous and sarcomatoid components shared 42% of somatic
single nucleotide variants (SSNVs). Sarcomatoid component
demonstrated a higher overall SSNV burden and increased
recurrent LOH on chromosomes 1p, 17p, 9, 10, 14, 18, and 22.
The sarcomatoid and carcinomatous components shared
some genes commonly found in clear cell RCC including
VHL. They also found biallelic TP53mutations in 32% of sar-
comatoid component; however, there was no TP53 mutations
in carcinomatous component. These ﬁndings provide solid
evidence that both components may arise from a common
progenitor or from a tiny subclone that could not be detected
by the present level of resolution (23). These discoveries are
important for the postoperative management of these tumors
as immune modulation or even vaccines may be incorporated
as part of adjuvant therapy with the hope of eliminating these
precursors and decreasing the chances of recurrence.
Pathology reporting
As an important prognostic factor, the presence of sarcoma-
toid RCC on pathologic examination is considered as one
of the most important ﬁndings by many clinicians; therefore,
clear statement of the presence of sarcomatoid component
should be an integral part of pathology report (4). The
amount of sarcomatoid component varied with a mean of
40%–50% (ranging from 1% to 100%) (5). Shuch et al.
found that an increased percentage of sarcomatoid compo-
nent is associated with a worse prognosis (7). Zhang et al.
also reported that the amount of sarcomatoid component is
greatly associated with patient’s death from RCC. Each
10% increase in the amount of sarcomatoid RCC was asso-
ciated with a 6% increased risk of death from RCC. Patients
with greater than 30% sarcomatoid component were 52%
more likely to die from RCC compared to patients with
less than 30% sarcomatoid component (29). The sarcomatoid
component includes ﬁbrous, leiomyomatous, rhabdoid,
osteoid, or chondroid transformations (5, 30, 31). These
uniform patterns of sarcomatoid RCC and the degree of
pleomorphism do not affect clinical behavior (2, 6, 30).
Coagulative tumor necrosis can be seen in 90% of sarcoma-
toid RCCs (6). In many cases, the RCC components are of
Fuhrman grade III or IV (5, 6). However, by convention, all
sarcomatoid RCCs are assigned to Fuhrman grade IV
because of the dismal prognosis (5, 6, 15, 32).
Appropriate pathology reporting is an important aspect of
cancer care. Shuch et al. reported that tumor classiﬁcation
was omitted in 28% of pathology reports, which may interfere
with the selection of systemic therapy and enrollment into
adjuvant clinical trials (33). Various terminologies have
been and are being used, such as sarcomatoid differentiation,
dedifferentiation (28), component, features, and progression.
With the progress of our understanding of the molecular/
genetic mechanisms driving sarcomatoid RCC, some of
these rather popular terms as “differentiation” may be obso-
lete and even misleading. The inconsistency may cause confu-
sion to the clinician. Since the sarcomatoid carcinoma
represents a high-grade tumor, its presence warrants a
separate diagnosis with an estimate of the proportion of
sarcomatoid component and RCC, similar to the reporting
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system of diffuse large B cell lymphoma transformation of
follicular lymphoma. The diffuse large cell lymphoma and
any co-existing follicular lymphoma component are reported
separately with their grades and percentages (34, 35).
Suggestion for a new pathology reporting
system
For the above reasons, the reporting of sarcomatoid RCC by
pathologists can be slightly modiﬁed. Reporting each compo-
nent separately can reﬂect the fact that the two components
diverge at a stem cell level and facilitate their ﬁling in and
retrieval from data bases.
The pathology report for sarcomatoid RCC can read
(1) RCC (subtypes, Fuhrman grade, and percentage) and
(2) sarcomatoid carcinoma (subtypes, Fuhrman grade IV,
and percentage).
We believe that enforcing the reporting in this way reﬂects
the molecular pathogenesis of sarcomatoid RCC and renders
reporting of the features and percentage of the sarcomatoid
RCC more uniform by pathologists. We hope that reporting
the two components separately may also encourage separate
molecular studies and search for targeted therapies for either
or both components.
Conclusion
This review highlights that the sarcomatoid component origi-
nates from the transformation of the pre-existing RCC, and
TP53 gene seems to play a pivotal role in this process. Since
the presence of a sarcomatoid component is closely associated
with outcome, thorough gross and histological examination is
critical. The presence and quantity of sarcomatoid compo-
nent are important for patient management and, therefore,
should be reﬂected in the pathology report.
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